We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
Read MoreHide Full Article
Allogene Therapeutics (ALLO - Free Report) announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.
These designations apply to three autoimmune diseases — systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM) and diffuse systemic sclerosis (SSc).
How Does the Fast Track Tag Benefit ALLO’s Drug Development?
Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, meet an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’
A candidate with the fast track designation is also eligible for rolling review. This could allow Allogene to submit completed sections of its regulatory filing for ALLO-329 to the FDA as they become available, rather than waiting for the entire application to be complete. This can potentially expedite the review process, as the FDA typically does not begin reviewing a submission until all sections of the application have been filed.
ALLO Stock’s Performance
Shares of Allogene have lost 33% year to date compared with the industry’s 7% decline.
Image Source: Zacks Investment Research
More on Allogene’s ALLO-329
Allogene intends to start the phase I RESOLUTION basket study in mid-2025, which will evaluate the safety and preliminary efficacy of ALLO-329 in SLE, IIM and SSc indications. The company expects to have proof-of-concept data from this study before this year’s end.
A next-generation allogeneic CAR T-cell therapy, ALLO-329, works by targeting both CD19+ B-cells and CD70+ activated T-cells. Additionally, this candidate incorporates Allogene’s proprietary Dagger technology, which is designed to reduce or eliminate the need for lymphodepletion (a preconditioning process that involves the use of chemotherapy).
ALLO’s Zacks Rank
Allogene currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $5.54 to $6.35. EPS estimates for 2026 have increased from $6.75 to $7.21 during the same period. Year to date, shares of ANIP have risen 21%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 17.32%.
In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to a profit of 25 cents. During the same timeframe, estimates for loss per share for 2026 have narrowed from 65 cents to 31 cents. Year to date, shares of the company have lost 58%.
CTMX’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 180.70%.
Estimates for 89bio’s loss per share have narrowed from $2.51 to $1.98 for 2025 in the past 60 days. During the same time frame, estimates for 2026 loss per share have improved from $2.94 to $2.15. ETNB’s shares have lost 30% year to date.
89bio’s earnings missed estimates in three of the trailing four quarters and beat the mark on one occasion, delivering an average negative surprise of 46.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
Allogene Therapeutics (ALLO - Free Report) announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.
These designations apply to three autoimmune diseases — systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM) and diffuse systemic sclerosis (SSc).
How Does the Fast Track Tag Benefit ALLO’s Drug Development?
Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, meet an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’
A candidate with the fast track designation is also eligible for rolling review. This could allow Allogene to submit completed sections of its regulatory filing for ALLO-329 to the FDA as they become available, rather than waiting for the entire application to be complete. This can potentially expedite the review process, as the FDA typically does not begin reviewing a submission until all sections of the application have been filed.
ALLO Stock’s Performance
Shares of Allogene have lost 33% year to date compared with the industry’s 7% decline.
Image Source: Zacks Investment Research
More on Allogene’s ALLO-329
Allogene intends to start the phase I RESOLUTION basket study in mid-2025, which will evaluate the safety and preliminary efficacy of ALLO-329 in SLE, IIM and SSc indications. The company expects to have proof-of-concept data from this study before this year’s end.
A next-generation allogeneic CAR T-cell therapy, ALLO-329, works by targeting both CD19+ B-cells and CD70+ activated T-cells. Additionally, this candidate incorporates Allogene’s proprietary Dagger technology, which is designed to reduce or eliminate the need for lymphodepletion (a preconditioning process that involves the use of chemotherapy).
ALLO’s Zacks Rank
Allogene currently carries a Zacks Rank #3 (Hold).
Allogene Therapeutics, Inc. Price
Allogene Therapeutics, Inc. price | Allogene Therapeutics, Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are ANI Pharmaceuticals (ANIP - Free Report) , CytomX Therapeutics (CTMX - Free Report) and 89bio (ETNB - Free Report) . While ANIP and CTMX sport a Zacks Rank #1 (Strong Buy) each at present, ETNB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $5.54 to $6.35. EPS estimates for 2026 have increased from $6.75 to $7.21 during the same period. Year to date, shares of ANIP have risen 21%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 17.32%.
In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to a profit of 25 cents. During the same timeframe, estimates for loss per share for 2026 have narrowed from 65 cents to 31 cents. Year to date, shares of the company have lost 58%.
CTMX’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 180.70%.
Estimates for 89bio’s loss per share have narrowed from $2.51 to $1.98 for 2025 in the past 60 days. During the same time frame, estimates for 2026 loss per share have improved from $2.94 to $2.15. ETNB’s shares have lost 30% year to date.
89bio’s earnings missed estimates in three of the trailing four quarters and beat the mark on one occasion, delivering an average negative surprise of 46.18%.